Physician profile
Kim Hui
NPI 1104963081
$5,258.67
in general payments reported to CMS, 2019-2025
39 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $226 · 2021: $170 · 2022: $288 · 2023: $857 · 2024: $1,447 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,476 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,476.32 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $776.53 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $474.17 | 2019-2023 | |
| Organon LLC | $427.01 | 2022-2025 | Jada System, Nexplanon |
| Mayne Pharma Commercial LLC | $361.22 | 2023-2025 | |
| Intuitive Surgical, INC. | $276.53 | 2019-2024 | |
| Hologic Sales and Service, LLC | $253.34 | 2020-2025 | Aptima, Acessa Provu System |
| Daiichi Sankyo INC. | $227.96 | 2023-2025 | Injectafer |
| Therapeuticsmd, INC. | $204.23 | 2019-2020 | |
| Exeltis, USA INC. | $195.44 | 2019-2024 | Slynd |
| Sumitomo Pharma America, INC. | $188.09 | 2023-2024 | Myfembree |
| Evofem Biosciences, INC. | $166.30 | 2024-2025 | Solosec, Phexx, Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $161.25 | 2019-2025 | |
| Allergan, INC. | $146.30 | 2019 | |
| Biogen, INC. | $130.33 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $116.67 | 2023-2024 | Ova1 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $110.56 | 2020-2022 | |
| Dermavant Sciences, INC. | $103.39 | 2023-2024 | Vtama |
| Millicent US INC | $99.39 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Ethicon US, LLC | $93.29 | 2019-2024 | Surgicel Nu-Knit, Vistaseal |
| Lupin INC. | $87.13 | 2019-2020 | |
| Pfizer INC. | $86.57 | 2024 | |
| Coopersurgical, INC. | $81.73 | 2019-2024 | Paragard T 380a |
| Roche Diagnostics Corporation | $75.29 | 2019 | |
| Myovant Sciences INC. | $43.54 | 2021 | |
| Biotissue Holdings INC. | $38.40 | 2025 | |
| Amag Pharmaceuticals, INC. | $38.23 | 2019 | |
| Duchesnay USA Incorporated | $35.28 | 2019 | |
| Lilly USA, LLC | $29.46 | 2025 | Mounjaro, Zepbound |
| Axonics, INC. | $28.60 | 2024 | Axonics |
| Avion Pharmaceuticals | $27.78 | 2019 | |
| Radius Health, INC. | $26.14 | 2020 | |
| Provepharm INC. | $25.85 | 2025 | Bludigo |
| Exact Sciences Corporation | $22.32 | 2025 | Cologuard Collection Kit |
| Teleflex LLC | $21.99 | 2025 | Quikclot |
| Merck Sharp & Dohme LLC | $18.29 | 2019 | |
| Meditrina | $16.24 | 2025 | |
| Vertical Pharmaceuticals, LLC | $15.89 | 2019 | |
| Novo Nordisk INC | $15.20 | 2023 | Saxenda, Wegovy |
| Minerva Surgical, INC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Hui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.